# A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia

> **NCT07743112** · PHASE2 · RECRUITING · sponsor: **Maxinovel Pty., Ltd.** · enrollment: 43 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** MAX-40279
- **DRUG:** Azacitidine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT07743112
- **Lead sponsor:** Maxinovel Pty., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-05
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743112, "A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07743112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*